Stock listing

NASDAQ:PMCB PharmaCyte Biotech, Inc. Stock

Home listing (NASDAQ) of PharmaCyte Biotech, Inc.

Follow PharmaCyte Biotech, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PMCB

$3.98 USD -0.58 (-12.8%)

Close on Nov 20, 2026

Past year -66.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.98 – $4.53 USDNov 20, 2026
Volume
16,203 sharesNov 20, 2026
Market cap
$2.25M USDAt the close on Nov 20, 2026 · price × 565,034 shares outstanding
52-week range
$3.98 – $28.69 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$25,864 USDMedian day 271 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
PharmaCyte Biotech, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PMCB · Home$3.975 USD-0.585 (-12.8%)16,203$4.48$4.53$3.975$4.56Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PMCB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.975-0.585-12.8%$4.48$4.53$3.97516,203
$4.56-0.81-15.1%$5.37$5.37$4.5621,319
$5.37-0.05-0.9%$5.512$5.512$5.356,331
$5.42-0.15-2.7%$5.60$5.855$5.407,379
$5.57-1.11-16.6%$6.65$6.65$5.4657,989
$6.68-0.958-12.5%$8.175$8.175$6.50127,077
$7.638+0.057+0.8%$7.408$7.961$6.8421,137
$7.581-0.059-0.8%$5.928$8.235$4.6913,515
$7.64-0.093-1.2%$7.648$7.874$7.222321
$7.733+0.893+13.1%$6.821$8.235$6.821507
$6.84-0.289-4.1%$6.908$7.203$6.821104
$7.129-0.11-1.5%$7.334$7.655$6.365565
$7.239+0.777+12.0%$6.403$7.999$6.4032,517
$6.462+0.566+9.6%$6.012$6.464$6.012176
$5.896+0.156+2.7%$5.89$6.08$5.89113
$5.74-0.57-9.0%$6.365$6.46$5.74337
$6.31-0.049-0.8%$6.646$7.216$6.27114
$6.359-0.16-2.4%$6.462$7.212$6.35949
$6.519-0.133-2.0%$6.603$7.098$6.46192
$6.652-0.097-1.4%$7.076$7.592$6.55532
$6.749+0.099+1.5%$6.595$7.596$6.494124
$6.65+0.051+0.8%$7.04$7.04$6.51991
$6.599+0.097+1.5%$6.527$6.965$6.527141
$6.502+0.004+0.1%$6.462$7.038$6.46269
$6.498+0.034+0.5%$6.462$7.068$6.46273
$6.464-0.327-4.8%$6.65$6.865$6.46291
$6.791+0.169+2.6%$6.498$6.886$6.498150
$6.622-0.141-2.1%$6.783$7.112$6.462112
$6.762-0.175-2.5%$6.821$7.106$6.65170
$6.937-0.747-9.7%$7.448$7.524$6.819336
$7.684+0.133+1.8%$7.756$7.883$7.429259
$7.551-0.156-2.0%$7.739$8.016$7.344593
$7.706-0.319-4.0%$7.923$8.018$7.621270
$8.026+0.614+8.3%$7.41$8.44$7.41643
$7.412-0.19-2.5%$7.60$7.782$7.317204
$7.602-0.072-0.9%$7.754$8.071$7.602124
$7.674-0.127-1.6%$7.94$8.33$7.632229
$7.801-0.16-2.0%$7.98$8.356$7.754536
$7.961-0.017-0.2%$8.132$8.487$7.961307
$7.978-0.401-4.8%$8.322$8.322$7.805394
$8.379-0.293-3.4%$8.569$9.006$8.361,110
$8.672+0.53+6.5%$8.132$8.848$8.132800
$8.142-0.57-6.5%$8.36$8.702$8.012668
$8.712+0.146+1.7%$8.442$8.782$8.44272
$8.565-0.169-1.9%$8.74$8.74$8.362278
$8.734+0.678+8.4%$7.828$9.074$7.7691,304
$8.056+0.148+1.9%$7.809$8.512$7.6231,281
$7.908+0.644+8.9%$7.125$9.50$7.1259,357
$7.264-0.184-2.5%$7.222$7.887$6.3442,880
$7.448-1.106-12.9%$8.389$8.586$6.651,653
$8.554+0.15+1.8%$8.366$8.892$8.174136
$8.404-0.627-6.9%$9.137$9.498$8.231337
$9.031-0.26-2.8%$9.308$9.472$8.841185
$9.291+0.047+0.5%$9.31$9.876$9.12638
$9.244-0.091-1.0%$9.50$9.517$9.225126
$9.335+0.201+2.2%$9.302$9.783$9.122380
$9.133-0.141-1.5%$9.215$9.473$8.934134
$9.274-0.243-2.6%$9.31$9.671$9.122153
$9.517-0.268-2.7%$9.88$10.07$9.12292
$9.785-0.479-4.7%$10.12$10.12$9.584231
$10.26-0.006-0.1%$10.46$10.74$10.09158
$10.27+0.017+0.2%$10.41$10.47$9.882204
$10.25+0.277+2.8%$9.88$10.26$9.709189
$9.975-0.152-1.5%$10.13$10.26$9.88172
$10.13+0.355+3.6%$9.842$10.26$9.795257
$9.772-0.344-3.4%$10.09$10.12$9.584257

Splits

3 splits since 2003 · NASDAQ:PMCB · every price before a split is adjusted for it

DayRatioWhat
1-for-19Consolidation
1-for-1500Consolidation
3-for-1Split
Ticker
NASDAQ:PMCB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All PharmaCyte Biotech, Inc. news

PharmaCyte Biotech, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 108 in all · newest Nov 13, 2026 · oldest 2019
Decks
4 decks · latest Mar 9, 2022

Where PharmaCyte Biotech, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PMCB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PMCBBOATSUnited StatesUSD

Valuation

Price/book 0.1× against a median of 0.5×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026

Enterprise value
−$15.59M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.1×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.97

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
PharmaCyte Biotech, Inc. · NASDAQ:PMCBUS$2.25M−US$15.59Mn/an/an/a0.1×n/a0.0×1.97
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
Modus Therapeutics Holding AB · OMXSTO:MODTXUS$2.22MUS$1.00Mn/an/an/a2.2×n/a0.0×n/a
Nuformix PLC · LSE:NFXUS$2.22MUS$1.00Mn/an/an/a1.0×n/a0.0×n/a
Medicus Pharma Ltd. · NASDAQ:MDCXUS$2.18M−US$2.73Mn/an/an/an/an/an/a2.03
Median of the othersUS$2.33MUS$1.00M0.7×1.5×0.5×−301.9%0.0×1.42

Team and board

Officers

OfficerRole
Joshua N. SilvermanInterim Chief Executive Officer, President, and Director
Carlos A. TrujilloChief Financial Officer
José IglesiasConsulting Chief Medical Officer

Board

DirectorRole
Jonathan L. SchechterDirector
Joshua N. SilvermanInterim Chief Executive Officer, President, and Director
Michael M. AbecassisDirector
Robert WeinsteinDirector
Wayne R. WalkerDirector

Events

Next results
Dec 17, 2026 (expected)
QuarterResultsShare move
Q1 2027Sep 14, 2026−15.1%
Q4 2026Jul 29, 2026+1.7%
Q3 2026Mar 17, 2026−0.1%
Q2 2026Dec 31, 2025+2.5%
Q1 2026Sep 15, 2025−2.9%
Q4 2025Jul 2, 2025−2.6%
Q3 2025Mar 17, 2025 · Before open0.0%
Q2 2025Dec 13, 2024 · After close−1.7%
Q1 2025Aug 13, 2024 · After close+2.2%
Q4 2024Jul 29, 2024 · After close0.0%
All 20 quarters
QuarterResultsShare move
Q3 2024Mar 18, 2024 · After close+6.5%
Q2 2024Dec 15, 2023 · After close+0.9%
Q1 2024Sep 18, 2023 · Before open−0.4%
Q4 2023Jul 31, 2023 · After close+0.4%
Q3 2023Mar 16, 2023 · After close+0.7%
Q2 2023Dec 14, 2022 · After close+3.1%
Q1 2023Sep 14, 2022 · After close+1.9%
Q4 2022Jul 28, 2022 · After close0.0%
Q3 2022Mar 15, 2022 · After close−0.5%
Q2 2022Dec 14, 2021 · After close+6.7%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2022)Investor deck44 slidesMar 9, 2022
Investor Presentation (September 2021)Investor deck40 slidesSep 10, 2021
BIO International Convention 2017Conference21 slidesJune 2017
Investor Presentation (May 2016)Investor deck34 slidesMay 29, 2016

Open Decks

Financings

RaiseDate
Private placement of series C convertible preferred stock and common stock purchase warrants
Closed: US$7M raised · US$1,000 a share · Warrants at US$1 for 60 months · GP Nurmenkari Inc.
Dealers: GP Nurmenkari Inc. (lead)
Use of proceeds: Strengthen balance sheet to support ongoing business initiatives and strategic growth opportunities
Aug 20, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue0000000000
Research and development391.3K438.4K407.4K468.5K690.9K916.2K301.2K460.1K2.00M1.18M
Operating income-6.85M-4.38M-8.52M-6.46M-4.39M-3.62M-3.83M-4.10M-6.98M-4.44M
Interest expense05093.05K453001.54K
Income before tax-19.4M30.7M
Income tax0000000000
Net income-19.4M30.7M333.8K-4.32M-4.24M-3.55M-3.83M-4.07M-6.83M-4.44M
Earnings per share, basic-2.773.19-1.80-0.22-0.27-2.45-4.230.00-0.01-0.01
Earnings per share, diluted-2.773.19-1.80-0.22-0.27-2.45-4.230.00-0.01-0.01

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents18.6M15.2M50.2M68.0M85.4M2.20M894.9K515.3K1.06M3.46M
Short-term investments254.0K366.3K0
Current assets37.4M22.4M50.4M68.1M85.5M2.28M1.04M653.4K1.28M3.54M
Total assets46.8M55.2M59.9M73.3M90.6M7.40M6.17M5.78M6.41M8.67M
Accounts payable271.1K399.2K389.4K128.3K205.4K172.3K185.8K121.9K352.6K365.6K
Current liabilities826.4K2.91M7.42M586.6K704.4K724.8K1.03M742.9K644.2K580.2K
Total liabilities11.8M3.28M20.4M586.6K704.4K724.8K1.08M742.9K644.2K580.2K
Shareholders' equity33.3M51.9M27.6M72.7M89.9M6.68M5.09M5.04M5.77M8.09M
Shares outstanding10.7M6.80M8.04M16.8M20.7M1.59M1.09M1.19B1.01B905.3M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-5.15M-2.98M-2.15M-3.79M-4.12M-3.33M-2.34M-2.88M-5.08M-3.34M
Cash from investing2.00M-7.00M-5.00M0000000
Cash from financing6.58M-25.0M-10.7M-13.6M87.3M4.64M2.73M2.34M2.68M4.88M
Share buybacks-401.6K-2.54M-28.2M-13.6M0
Change in cash3.43M-35.0M-17.9M-17.4M83.2M1.31M379.6K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D/A · Big-stake notice, amendedNov 20, 2026Big-stake noticeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
8-K · Current reportNov 19, 2026Acquisition or disposalSEC
8-K · Current reportNov 13, 2026Current reportSEC
8-K · Current reportOct 16, 2026Current reportSEC
10-Q · Quarterly reportSep 14, 2026Quarterly reportSEC
10-K · Annual reportJul 29, 2026Annual reportSEC
4/A · Change in ownership, amendedJul 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 17, 2026Insider tradeSEC
4/A · Change in ownership, amendedJul 17, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4/A · Change in ownership, amendedJul 17, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Management or board changeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2026Big-stake noticeSEC
10-Q · Quarterly reportMar 17, 2026Quarterly reportSEC
ARS · Annual report to shareholdersMar 9, 2026Annual reportSEC
DEF 14A · Proxy statementMar 9, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementFeb 27, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
10-Q · Quarterly reportDec 18, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeDec 15, 2025Explanation requestSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
4 · Change in ownershipDec 12, 2025Insider tradeSEC
8-K · Current reportDec 5, 2025Current reportSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 18, 2025Big-stake noticeSEC
8-K/A · Current report, amendedNov 18, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportOct 31, 2025Management or board changeSEC
DEF 14A · Proxy statementOct 6, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveSep 29, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementSep 24, 2025Meeting noticeSEC
CORRESP · Letter to the SECSep 24, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 23, 2025Other filingsSEC
S-3 · Registration statementSep 16, 2025Offer documentSEC
10-Q · Quarterly reportSep 15, 2025Quarterly reportSEC
8-K · Current reportSep 5, 2025Acquisition or disposalSEC
DSep 3, 2025Other filingsSEC
8-K · Current reportAug 18, 2025Material contractSEC
10-K · Annual reportAug 8, 2025Annual reportSEC
NT 10-K · Late filing noticeJul 29, 2025Explanation requestSEC
8-K · Current reportApr 24, 2025Meeting outcomeSEC
10-Q · Quarterly reportMar 17, 2025Quarterly reportSEC
ARS · Annual report to shareholdersMar 10, 2025Annual reportSEC
DEFA14A · Additional proxy materialMar 10, 2025Meeting noticeSEC
DEF 14A · Proxy statementMar 10, 2025Meeting noticeSEC
8-K · Current reportFeb 26, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportDec 13, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansDec 4, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportSep 16, 2024Quarterly reportSEC
NT 10-Q · Late filing noticeSep 16, 2024Explanation requestSEC
10-K · Annual reportAug 13, 2024Annual reportSEC
NT 10-K · Late filing noticeJul 29, 2024Explanation requestSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 30, 2024Insider tradeSEC
SC 13D · Big-stake noticeMay 30, 2024Big-stake noticeSEC
8-K · Current reportMay 23, 2024Acquisition or disposalSEC
8-K · Current reportMay 1, 2024Meeting outcomeSEC
DEF 14A · Proxy statementMar 27, 2024Meeting noticeSEC
ARS · Annual report to shareholdersMar 27, 2024Annual reportSEC
10-Q · Quarterly reportMar 18, 2024Quarterly reportSEC
SC 13G · Big-stake noticeFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
10-Q · Quarterly reportDec 15, 2023Quarterly reportSEC
3 · Initial statement of ownershipNov 28, 2023Insider tradeSEC
8-K · Current reportNov 24, 2023Management or board changeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
4 · Change in ownershipNov 22, 2023Insider tradeSEC
SC 13D · Big-stake noticeNov 22, 2023Big-stake noticeSEC
8-K · Current reportNov 15, 2023Material contractSEC
8-K · Current reportNov 9, 2023Current reportSEC
EFFECT · Notice that a registration is effectiveOct 2, 2023Other filingsSEC
CORRESP · Letter to the SECSep 27, 2023Other filingsSEC
S-3/A · Registration statement, amendedSep 21, 2023Offer documentSEC
10-Q · Quarterly reportSep 18, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeSep 15, 2023Explanation requestSEC
S-3/A · Registration statement, amendedSep 11, 2023Offer documentSEC
8-K · Current reportSep 7, 2023Meeting outcomeSEC
CORRESP · Letter to the SECAug 4, 2023Other filingsSEC
S-3/A · Registration statement, amendedAug 4, 2023Offer documentSEC
8-K · Current reportAug 4, 2023Current reportSEC
10-K · Annual reportJul 31, 2023Annual reportSEC
DEF 14A · Proxy statementJul 31, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementJul 19, 2023Meeting noticeSEC
8-K · Current reportJul 18, 2023Current reportSEC
UPLOAD · Letter from the SECJun 26, 2023Other filingsSEC
SC 13D/A · Big-stake notice, amendedJun 16, 2023Big-stake noticeSEC
SC TO-I/AJun 15, 2023Acquisition or disposalSEC
S-3 · Registration statementJun 9, 2023Offer documentSEC
DEF 14A · Proxy statementJun 5, 2023Meeting noticeSEC
CORRESP · Letter to the SECJun 5, 2023Other filingsSEC
CORRESP · Letter to the SECMay 30, 2023Other filingsSEC
PRE 14A · Preliminary proxy statementMay 25, 2023Meeting noticeSEC
SC 13G · Big-stake noticeMay 19, 2023Big-stake noticeSEC
UPLOAD · Letter from the SECMay 19, 2023Other filingsSEC
SC 13D/A · Big-stake notice, amendedMay 12, 2023Big-stake noticeSEC
SC TO-IMay 11, 2023Acquisition or disposalSEC
8-K · Current reportMay 11, 2023Material contractSEC
10-Q · Quarterly reportMar 16, 2023Quarterly reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2023Big-stake noticeSEC
8-K · Current reportFeb 2, 2023Current reportSEC
SC 13G/A · Big-stake notice, amendedJan 10, 2023Big-stake noticeSEC
3 · Initial statement of ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
4 · Change in ownershipDec 30, 2022Insider tradeSEC
8-K · Current reportDec 30, 2022Meeting outcomeSEC
10-Q · Quarterly reportDec 14, 2022Quarterly reportSEC
DEF 14A · Proxy statementNov 25, 2022Meeting noticeSEC
8-K · Current reportNov 18, 2022Management or board changeSEC
3 · Initial statement of ownershipNov 16, 2022Insider tradeSEC
PRE 14A · Preliminary proxy statementNov 15, 2022Meeting noticeSEC
8-K · Current reportNov 7, 2022Management or board changeSEC
SC 13G · Big-stake noticeOct 20, 2022Big-stake noticeSEC
8-K · Current reportOct 14, 2022Management or board changeSEC
8-K · Current reportOct 7, 2022Management or board changeSEC
10-Q · Quarterly reportSep 14, 2022Quarterly reportSEC
3 · Initial statement of ownershipAug 24, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 23, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 23, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 23, 2022Insider tradeSEC
3 · Initial statement of ownershipAug 23, 2022Insider tradeSEC
8-K · Current reportAug 15, 2022Material contractSEC
DEFA14A · Additional proxy materialAug 15, 2022Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedAug 15, 2022Big-stake noticeSEC
10-K · Annual reportJul 28, 2022Annual reportSEC
8-K · Current reportJul 28, 2022Current reportSEC
DEFA14A · Additional proxy materialJul 28, 2022Meeting noticeSEC
DFAN14AJul 28, 2022Other filingsSEC
PREC14AJul 26, 2022Other filingsSEC
8-K · Current reportJul 21, 2022Current reportSEC
DEFA14A · Additional proxy materialJul 21, 2022Meeting noticeSEC
8-K · Current reportJul 19, 2022Current reportSEC
DEFA14A · Additional proxy materialJul 19, 2022Meeting noticeSEC
DFAN14AJul 11, 2022Other filingsSEC
SC 13D/A · Big-stake notice, amendedJul 11, 2022Big-stake noticeSEC
8-K · Current reportJul 11, 2022ResultsSEC
DEFA14A · Additional proxy materialJul 11, 2022Meeting noticeSEC
DFAN14AJul 5, 2022Other filingsSEC
DFAN14AJun 23, 2022Other filingsSEC
SC 13D/A · Big-stake notice, amendedJun 23, 2022Big-stake noticeSEC
8-K · Current reportJun 15, 2022Current reportSEC
DEFA14A · Additional proxy materialJun 15, 2022Meeting noticeSEC
8-K · Current reportJun 6, 2022Current reportSEC
8-K · Current reportApr 13, 2022Management or board changeSEC
3 · Initial statement of ownershipApr 11, 2022Insider tradeSEC
8-K · Current reportApr 5, 2022Management or board changeSEC
10-Q · Quarterly reportMar 15, 2022Quarterly reportSEC
8-K · Current reportMar 9, 2022Current reportSEC
8-K · Current reportFeb 28, 2022Current reportSEC
8-K · Current reportFeb 17, 2022Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 11, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 4, 2022Big-stake noticeSEC
10-Q · Quarterly reportDec 14, 2021Quarterly reportSEC
424B3 · ProspectusNov 19, 2021Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 18, 2021Other filingsSEC
CORRESP · Letter to the SECNov 15, 2021Other filingsSEC
UPLOAD · Letter from the SECNov 15, 2021Other filingsSEC
S-3 · Registration statementNov 5, 2021Offer documentSEC
SC 13D · Big-stake noticeNov 4, 2021Big-stake noticeSEC
10-Q · Quarterly reportSep 14, 2021Quarterly reportSEC
8-K · Current reportSep 9, 2021Current reportSEC
3 · Initial statement of ownershipSep 3, 2021Insider tradeSEC
DAug 31, 2021Other filingsSEC
3 · Initial statement of ownershipAug 31, 2021Insider tradeSEC
3 · Initial statement of ownershipAug 31, 2021Insider tradeSEC
3 · Initial statement of ownershipAug 31, 2021Insider tradeSEC
SC 13G · Big-stake noticeAug 30, 2021Big-stake noticeSEC
SC 13G · Big-stake noticeAug 30, 2021Big-stake noticeSEC
424B5 · ProspectusAug 23, 2021Offer documentSEC
8-K · Current reportAug 23, 2021Material contractSEC
3 · Initial statement of ownershipAug 20, 2021Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2021Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2021Insider tradeSEC
S-3MEFAug 19, 2021Other filingsSEC
8-K · Current reportAug 11, 2021Material contractSEC
CERT · Exchange's certificate of listingAug 10, 2021Other filingsSEC
10-K · Annual reportAug 10, 2021Annual reportSEC
424B5 · ProspectusAug 10, 2021Offer documentSEC
8-K · Current reportAug 2, 2021Current reportSEC
424B5 · ProspectusAug 2, 2021Offer documentSEC

This page holds 200 of 476 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from PharmaCyte Biotech, Inc.’s releases · as of Nov 13, 2026

Common shares
565,034
Fully diluted
565,034

Fully diluted

LineSharesAs of
Common shares565,034Nov 13, 2026

Warrants and options

Lot
Warrants · US$1.00 · expire about Aug 2030

Share count over time

CountShares
Nov 13, 2026565,034
Nov 13, 2026
Nov 11, 2026
Nov 11, 2026
Nov 11, 202610,755,649

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Citadel140K1.3%US$57,654Sep 30, 2026
Geode Capital124K1.2%US$50,892Sep 30, 2026
Vanguard80,2300.75%US$32,975Sep 30, 2026
Renaissance Technologies64,7380.60%US$26,581Sep 30, 2026
Jane Street64,1530.60%US$26,341Sep 30, 2026
Northern Trust32,6240.30%US$13,395Sep 30, 2026
XTX Topco Ltd30,3860.28%US$12,476Sep 30, 2026
Susquehanna30,0630.28%US$12,344Sep 30, 2026
StoneX Group Inc.30,0060.28%US$12,321Sep 30, 2026
Schonfeld Strategic Advisors LLC26,2470.24%US$10,777Sep 30, 2026
All 24 holders
HolderSharesOf the companyValueAs of
Equitec Proprietary Markets, LLC22,2270.21%US$9,126Sep 30, 2026
Ground Swell Capital, LLC19,6120.18%US$8,053Sep 30, 2026
Commonwealth Equity Services, LLC10,2550.10%US$4,210Sep 30, 2026
Tower Research Capital LLC (TRC)4,8730.05%US$2,001Sep 30, 2026
Allworth Financial LP714<0.01%US$294Sep 30, 2026
Osaic Holdings, Inc.303<0.01%US$126Sep 30, 2026
Covestor Ltd275<0.01%Sep 30, 2026
Keating Financial Advisory Services, Inc.134<0.01%US$55Sep 30, 2026
UBS30<0.01%US$12Sep 30, 2026
Bfsg, LLC5<0.01%US$3Sep 30, 2026
Barclays4<0.01%US$2Sep 30, 2026
Financial Consulate, Inc2<0.01%US$1Sep 30, 2026
NewEdge Advisors, LLC2<0.01%US$1Sep 30, 2026
BlackRock1<0.01%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund102K0.95%US$84,748May 31, 2026
Vanguard Extended Market Index Fund56,7780.53%US$43,719Jun 30, 2026
Fidelity Nasdaq Composite Index Fund26,2110.24%US$21,870May 31, 2026
Fidelity Total Market Index Fund15,2560.14%US$12,730May 31, 2026
Fidelity Series Total Market Index Fund12,8960.12%US$10,760May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Ayrton Capital LLC9.90%774KDec 31, 2024Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Joshua N. Silverman
Other companies: Femasys Inc. (Director · Since at least Nov 21, 2023); TAO Synergies Inc. (Executive Chairman · Since at least Jun 4, 2021); Petros Pharmaceuticals Inc (Vice-Chairman of the Board · Since at least Dec 1, 2020); Q/C Technologies, Inc. (Executive Chairman · Since at least Sep 6, 2018); Fabric.AI, Inc. (Chief Executive Officer, Director · Since at least Aug 15, 2016); Marker Therapeutics, Inc. (Director · Nov 28, 2016 – Oct 16, 2018 · Past); Neurotrope Inc (Director · Aug 4, 2016 – Dec 1, 2020 · Past); Protagenic Therapeutics, Inc. (Director · Feb 12, 2016 – Feb 21, 2020 · Past); MGT Capital Investments, Inc. (Director · Dec 31, 2015 – Dec 31, 2015 · Past); National Holdings Corporation (Director · Jul 28, 2014 – Sep 12, 2016 · Past)
Interim Chief Executive Officer, President, and Director · Since at least Aug 15, 2022
Jack E Stover
Other companies: TransCode Therapeutics, Inc. (Director · Since at least Dec 19, 2025); Profusa, Inc. (Chief Executive Officer · Since at least Dec 20, 2021); Traws Pharma, Inc. (Director · Since at least May 18, 2016); Antares Pharma Inc (President and CEO, Director · Jan 25, 2006 – May 14, 2008 · Past); Interpace Biosciences, Inc. (President and CEO, Director · Aug 3, 2005 – Mar 12, 2020 · Past)
Director · Aug 15, 2022 – Aug 15, 2022 · Past
Robert Weinstein
Other companies: Petros Pharmaceuticals Inc (Chief Accounting Officer · Since at least Jun 18, 2026); TAO Synergies Inc. (Chief Financial Officer · Since at least Jun 4, 2021); XWELL, Inc. (Director & Chair of Audit Committee · Since at least Feb 3, 2020); TaoWeave, Inc. (Director · May 29, 2023 – May 29, 2023 · Past); Neurotrope Inc (See Remarks · Nov 13, 2015 – Dec 1, 2020 · Past)
Director · Since at least Nov 14, 2022
Wayne Walker
Other companies: Pitney Bowes Inc. (Board Member · Since at least Sep 12, 2025); Outdoor Holding Company (Director · Since at least Nov 3, 2022); Fabric.AI, Inc. (Director · Since at least Dec 17, 2020); Petros Pharmaceuticals Inc (Board of Directors · Since at least Dec 1, 2020); Wrap Technologies, Inc. (Director · Nov 14, 2018 – Jul 7, 2023 · Past)
Director · Since at least Dec 28, 2022
Jonathan L. Schechter
Other companies: TaoWeave, Inc. (Director · Since at least May 29, 2023); TAO Synergies Inc. (Director · Since at least Jun 4, 2021); Neurotrope Inc (Director · Mar 15, 2019 – Dec 1, 2020 · Past)
Director · Since at least Aug 15, 2022
Daniel Allen
Other companies: SharpSpring Inc (Director · Apr 23, 2019 – Jul 24, 2019 · Past)
Director · Aug 15, 2022 – Dec 28, 2022 · Past
Thomas C K Yuen
Other companies: SRS Labs Inc (CEO, Chairman of the Board, Director · Jun 8, 2010 – Jul 20, 2012 · Past)
Director · Aug 10, 2021 – Aug 10, 2021 · Past
Carlos A. TrujilloChief Financial Officer · Since at least Nov 5, 2026
Daniel Stuart FarbDirector · Aug 15, 2022 – Dec 28, 2022 · Past
José IglesiasConsulting Chief Medical Officer · Since at least Nov 5, 2026
All 13 people
PersonSeat
Michael M. AbecassisDirector · Since at least Aug 10, 2021
Raymond CF TongDirector · Aug 10, 2021 – Aug 10, 2021 · Past
Thomas LiquardDirector · Aug 10, 2021 – Aug 10, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about PharmaCyte Biotech, Inc.